Results Lead to Groundbreaking Decision from Federal Agency
(May 22, 2015) As a
result of research performed by scientists at the University of Maryland School
of Medicine (UM SOM), the U.S. Food and Drug Administration has approved the
use of a drug to treat the deleterious effects of radiation exposure following
a nuclear incident. The drug, Neupogen®, is the first ever approved for the
treatment of acute radiation injury.
The research was done by Thomas J. MacVittie, PhD,
professor, and Ann M. Farese, MA, MS, assistant professor, both in the
University of Maryland School of Medicine (UM SOM) Department of Radiation
Oncology’s Division of Translational Radiation Sciences. The investigators did
their research in a non-human clinical model of high-dose radiation.